There are 487 resources available
Invited Discussant LBA60 and 1402MO
Presenter: Radka Obermannova
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast
LBA63 - A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy
Presenter: Hanneke Wilmink
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
1504MO - Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
Presenter: Wungki Park
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA63 and 1504MO
Presenter: Arndt Vogel
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast
965MO - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW
Presenter: Thomas Decaens
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
947MO - Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Lorenza Rimassa
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
74MO - Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1
Presenter: Kyosuke Seguchi
Session: Mini oral session: Basic science & Translational research
Resources:
Abstract
Slides
Webcast
Invited Discussant 965MO and 947MO
Presenter: James Harding
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast
Welcome
Presenter: Umberto Malapelle
Session: Illumina - Liquid biopsy-based biomarkers for cancer profiling and monitoring: current and future applications
Resources:
Webcast
Implementation in clinical practice of therapeutic drug monitoring (TDM) of kinase inhibitors anno 2024
Presenter: Ron Mathijssen
Session: Current advances in clinical pharmacology within oncology, and its relevance for daily practice
Resources:
Slides
Webcast